To the Editor The 2 Viewpoints1,2 debating adjuvant locoregional radiation therapy in the setting of intermediate-risk breast cancer (patients with 1-3 positive lymph nodes,3,4 internal tumor location,3 or node negative but with high-risk features4) resume the current discussions in tumor boards following publication of these pivotal trials.3,4 However, several questions emerge.